13,184 Shares in GSK plc (NYSE:GSK) Bought by Brucke Financial Inc.

Brucke Financial Inc. acquired a new stake in GSK plc (NYSE:GSK - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 13,184 shares of the pharmaceutical company's stock, valued at approximately $465,000.

Several other hedge funds have also recently bought and sold shares of GSK. FMR LLC increased its stake in GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after buying an additional 23,814,104 shares during the period. Primecap Management Co. CA boosted its position in GSK by 70.1% in the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after buying an additional 10,407,905 shares during the period. Voloridge Investment Management LLC grew its stake in shares of GSK by 1,360.4% in the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after acquiring an additional 2,016,795 shares in the last quarter. Bridgewater Associates LP grew its stake in shares of GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock worth $76,017,000 after acquiring an additional 1,281,855 shares in the last quarter. Finally, Woodline Partners LP purchased a new stake in shares of GSK during the fourth quarter worth $36,665,000. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Stock Up 2.6%

Shares of GSK stock traded up $1.03 during trading hours on Friday, hitting $41.03. The company had a trading volume of 7,371,682 shares, compared to its average volume of 4,872,127. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The company's 50-day moving average is $37.33 and its two-hundred day moving average is $36.15. The company has a market cap of $84.65 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.01.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 EPS. Analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a $0.4216 dividend. This represents a $1.69 annualized dividend and a yield of 4.11%. The ex-dividend date is Friday, May 16th. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is 86.60%.

Analysts Set New Price Targets

Several research firms recently commented on GSK. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday. Finally, Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.